Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in AGL?
ANGLE plc: THE INVESTMENT CASE

Broker targeting near-tripling in ANGLE's share price as Parsortix development strides forward

In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
Cancer cells
INVESTMENT OVERVIEW: AGL The Big Picture
The analysts noted that ANGLE is addressing a substantial market, estimated to be worth as much as £8bn

‘House’ broker finnCap is targeting a 100p share price for revenue-generating medical diagnostics company ANGLE PLC (LON:ANG), which would be a near tripling from the AIM-listed firm’s current share price of around 35p.

In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells (CTCs) from a patient’s blood sample.

READ: ANGLE says research further demonstrates key advantages of Parsortix system for cancer treatment

Launched into the research market in 2016, the analysts pointed out that Parsortix is gaining traction in leading cancer centres and with eminent key opinion leaders, which they think should accelerate if, as the analysts expect, US Food & Drug Administration clearance is achieved in late 2018/early 2019.

In an announcement yesterday, ANGLE highlighted the publication of independent research which further showed the key advantages of its Parsortix system in the treatment of cancers.

The AIM-listed liquid biopsy firm said the research published by the Heinrich Heine University of Duesseldorf in the International Journal of Molecular Science demonstrated the measurement of key proteins in breast cancer using Parsortix, which may advise therapy decisions in breast cancer treatment.

The group said the Dusseldorf study of 47 metastatic breast cancer patients showed that ANGLE’s Parsortix system harvests clinically relevant cancer cells for analysis that other systems miss.

In their note published today, finnCap’s analyst said ANGLE aims to be a leading player in the liquid biopsy market “by carving out clear, differentiated clinical applications for Parsortix – for use as high-risk diagnostic screening or therapeutic decision-making tools as well as for monitoring patients during (efficacy) as well as after therapy (recurrence).”

They added: “Its high level of accuracy and low false positive rate lend Parsortix to all solid tumours, potentially reducing the number of invasive follow-up procedures (eg tissue biopsy) that either may be inaccessible or are expensive, resource-intensive and carry increased risk.”

Addressable market estimated to be worth as much as £8bn

The analysts noted that ANGLE is addressing a substantial market, estimated to be worth as much as £8bn, but initially in three clinical applications worth around £4.6bn.

Pilot studies undertaken by its network are also looking at CTCs in other large cancer populations – colorectal, head & neck and lung and cancers.

The analysts said their punchy target price, based on a discounted cashflow analysis, also takes account of the requirement for up to £15mln of additional capital to fund ANGLE’s R&D and commercialisation activities, which could be in the form of equity, debt, grant or partnership funding.

They concluded: “Value lies in ANGLE's ability to position Parsortix where there is a clear and differentiated clinical need in an addressable market of c.£8bn.”

View full AGL profile View Profile

ANGLE plc Timeline

Newswire
October 12 2017

Related Articles

mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
worried man on bed
October 16 2017
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”
lupus poster
Thu
The last of the 200 patients has had their final assessment and the data is now being processed and analysed

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use